Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

16.67USD
2:29pm EDT
Change (% chg)

$-1.23 (-6.84%)
Prev Close
$17.90
Open
$17.85
Day's High
$18.00
Day's Low
$16.40
Volume
66,252
Avg. Vol
101,423
52-wk High
$18.40
52-wk Low
$7.03

EPZM.OQ

Chart for EPZM.OQ

About

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of... (more)

Overall

Beta: 2.40
Market Cap(Mil.): $1,044.61
Shares Outstanding(Mil.): 58.36
Dividend: --
Yield (%): --

Financials

  EPZM.OQ Industry Sector
P/E (TTM): -- 142.93 17.37
EPS (TTM): -2.07 -- --
ROI: -46.80 2.34 -5.89
ROE: -52.85 0.22 -5.30

BRIEF-Epizyme quarterly loss per share $0.56

* Quarterly loss per share $0.56 Source text: (http://bit.ly/2qgKGVs) Further company coverage:

May 08 2017

BRIEF-Epizyme Earns $10 million milestone payment from Glaxosmithkline

* Epizyme earns $10 million milestone payment from glaxosmithkline for initiation of GLP Toxicology studies with novel methyltransferase inhibitor

May 04 2017

BRIEF-Epizyme announces tazemetostat fast track designation for follicular lymphoma and plenary session on Phase 2 NHL data at ICML

* Epizyme announces tazemetostat fast track designation for follicular lymphoma and plenary session on Phase 2 NHL data at ICML

Apr 25 2017

BRIEF-Epizyme qtrly loss per share $0.60

* Epizyme reports 2016 financial results and provides 2017 pipeline goals

Mar 09 2017

BRIEF-Epizyme elects Kevin Conroy to its board of directors

* Epizyme elects Kevin Conroy to its board of directors Source text for Eikon: Further company coverage:

Feb 07 2017

BRIEF-Epizyme receives positive written response from FDA allowing enrollment of patients with follicular lymphoma in U.S.

* Epizyme Inc - received a positive written response from FDA allowing enrollment of patients with follicular lymphoma in U.S.

Jan 19 2017

BRIEF-Epizyme announces fast track designation for Tazemetostat in DLBCL

* Epizyme announces fast track designation for tazemetostat in DLBCL and provides solid tumor program update

Nov 28 2016

More From Around the Web

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥5,983 -12.00
Novartis AG (NOVN.S) CHF79.40 +0.65
GlaxoSmithKline plc (GSK.L) 1,642.00 -5.50
Celgene Corporation (CELG.OQ) $115.45 -1.48

Earnings vs. Estimates